Our present results confirm and extend the latter observations and support the hypothesis that the concomitant inhibition of the NF-kB family and prolonged activation of NRF2 together with its target HO-1 may shift the balance toward CLL cell death. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.